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Abstract
Background: A subset of patients with multiple sclerosis (MS) shows an increased endogenous IFN-like activity before
initiation of IFN-beta treatment. The molecular basis of this phenomenon and its relevance to predict individual therapy
outcomes are not yet fully understood. We studied the expression patterns of these patients, the prognostic value of an
elevated IFN-like activity, and the gene regulatory effects of exogenously administered IFN-beta.
Methods: Microarray gene expression profiling was performed for 61 MS patients using peripheral blood mononuclear
cells obtained before and after 1 month of IFN-beta therapy. Expression levels of genes involved in pathways either
inducing or being activated by IFN-beta were compared between patients with high (MX1high cohort) and low (MX1low
cohort) endogenous IFN-like activity. Patients were followed for 5 years and relapses as well as progression on the
expanded disability status scale (EDSS) were documented.
Results: Before the start of therapy, 11 patients presented elevated mRNA levels of IFN-stimulated genes indicative of a
relatively high endogenous IFN-like activity (MX1high). In these patients, pathogen receptors (for example, TLR7, RIG-I and
IFIH1) and transcription factors were also expressed more strongly, which could be attributed to an overactivity of
IFN-stimulated gene factor 3 (ISGF3, a complex formed by STAT1, STAT2 and IFN regulatory factor 9). After 1 month of
IFN-beta therapy, the expression of many pathway genes was significantly induced in MX1low patients, but remained
unaltered in MX1high patients. During follow-up, relapse rate and changes in EDSS were comparable between both
patient groups, with differences seen between different types of IFN-beta drug application.
Conclusions: Therapeutic IFN-beta induces the transcription of several genes involved in IFN-related pathways. In a
subgroup of MS patients, the expression of these genes is already increased before therapy initiation, possibly driven by
an overexpression of ISGF3. Patients with high and low endogenous IFN-like activity showed similar clinical long-term
courses of disease. Different results were obtained for different IFN-beta drug preparations, and this merits further
investigation.
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Background
Multiple sclerosis (MS) is a chronic inflammatory disease
causing neuronal demyelination and axonal decay in the
central nervous system. The impaired nerve conduction
results in progressive neurological dysfunctions, ultimately
leading to severe impairment of the patient [1]. No distinct
etiology has so far been determined, but autoimmune pro-
cesses, genetic dispositions and environmental factors
have been associated with the disease [1-5]. The individual
course of MS is highly heterogeneous making predictions
of long-term prognosis challenging. The majority of
patients experience a relapsing-remitting type of MS (RR-
MS) during the first years of disease with episodically
flourishing neurological dysfunctions [6-8]. To date, no
curative therapy is available. An immunomodulatory ther-
apy with IFN-beta is a common first-line approach for
controlling exacerbations and progression in RR-MS.
Three drug formulations of IFN-beta are available:
subcutaneous (sc) IFN-beta-1a and IFN-beta-1b, and
intramuscular (im) IFN-beta-1a [9,10]. The molecular
mechanisms of action of these drugs have been studied ex-
tensively over the past years [11,12]. IFN-beta therapy,
however, proved only partially effective, with a subset of
patients not sufficiently responding to therapy. This means
that, despite treatment, further disease progression can be
observed in terms of relapses, worsening on the expanded
disability status scale (EDSS), or formation of new brain
lesions [13].
A recent focus of research has been the search for mo-
lecular biomarkers that can assist in diagnosis as well as
in monitoring of disease activity and therapeutic effects.
In this context, biomarkers are sought to predict long-
term disease progression and individual therapy
response with the aim of reducing the delay of effective
therapy and lowering socioeconomic costs on ineffective
drug applications [14,15]. However, none of the poten-
tially prognostic biomarker candidates have so far been
established and implemented in clinical practice. More
than a hundred genes have been proposed as blood
biomarkers, but most could not be independently con-
firmed in a recent study [16]. One widely accepted
explanation for IFN-beta therapy failure is the formation
of neutralizing antibodies (NAb). This occurs after a few
months of treatment in 7 % to 35 % of the patients,
dependent on the drug formulation [17]. NAbs are anti-
bodies against recombinant IFN-beta that diminish its
ability to induce the transcription of interferon-
stimulated genes (ISGs) and hence reduce the bioactivity
and the long-term clinical effects of the drug [18,19].
Thus far, hundreds of ISGs have been identified. They
show a strong co-regulation upon stimulation with type
I IFNs (IFN-alpha and IFN-beta) [20,21]. The mRNA in-
duction of ISGs by IFN-beta therapy (in the absence of
NAbs) has been demonstrated to be relatively short-
lasting, with many ISGs returning to pre-treatment
levels within 4 days [22,23]. One of the most prominent
ISGs is myxovirus resistance protein 1 (MX1 or MxA).
The blood expression of MX1 has been shown to reflect
the immunoregulatory activity of IFN-beta, and hence
MX1 has been clinically implemented to measure the
effects of IFN-beta administration on gene regulation
and to detect the presence of NAbs [24,25].
While MX1 is a useful biomarker during IFN-beta
treatment, it has been debated whether already prior to
treatment the expression of MX1 or other ISGs allows
the prediction of individual long-term clinical outcomes.
It has been observed that a subgroup of therapy-naïve
MS patients shows an elevated endogenous ISG expres-
sion and, thus, an increased type I IFN-like activity [26].
Based on this finding, van Baarsen et al. [27] suggested
that the pre-treatment IFN signature in the peripheral
blood could serve as a prognostic biomarker of clinical
responses to IFN-beta therapy. Comabella et al. [28,29]
later reported an overexpression of ISGs before the start
of IFN-beta treatment in clinical non-responders com-
pared to responders. They observed that, upon treat-
ment, the expression of these genes remained unaltered
in non-responders, but was strongly upregulated in
responders. They attributed the elevated IFN signature
to increased amounts of phosphorylated STAT1 and
IFN-alpha/beta receptor 1 (IFNAR1) in monocytes.
Moreover, higher baseline levels of IFN-beta itself were
detected in non-responders by Axtell et al. [30] and this
was later confirmed by Bustamante et al. [29]. On the
other hand, Feng et al. [31] detected a lower expression
of ISGs in patients with active MS and found that this
was linked to a subnormal phosphorylation of the tran-
scription factor (TF) STAT1. They concluded that a de-
fect in type I IFN signaling may predict the course of
disease and responses to therapy. Recently, van der
Voort et al. [32] studied a group of 116 RR-MS patients
and observed that high MX1 mRNA levels in the blood
were significantly associated with a longer time to a first
new relapse. A potentially beneficial effect of an elevated
endogenous type I IFN response was also reported by
Hesse et al. [33], who described a positive correlation of
MX1 expression and IL-10 expression, and a negative
correlation of IL-10 expression and disease activity on
magnetic resonance imaging in untreated MS patients.
The results of these studies have been somewhat
inconsistent, possibly due to differences in the type of
specimen analyzed, measurement technology, treatment
strategy, definition of disease progression, and data ana-
lysis. Hence, there is a need to independently validate
whether the individual IFN signaling activity, reflected
by the expression of MX1 and other ISGs, can predict
the individual course of disease. Moreover, the under-
lying molecular physiology of type I IFN-like activity and
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the effects of IFN-beta therapy on the IFN-beta-related
pathways have so far not been elucidated in a compre-
hensive manner. A deeper insight into these effects may
help to better understand the mechanisms of action of
the drug and to disclose transcript-based disease
heterogeneity.
In this work, we investigated the molecular basis of high
endogenous IFN-like activity by studying the pathways
involved in IFN regulation and signaling. Furthermore, we
analyzed the gene regulatory effects of IFN-beta therapy
and the expression differences between MS patients with
low and high pre-treatment IFN-like activity. To evaluate
the prognostic power of this activity on therapy success,




To unravel the molecular basis that accounts for individ-
ual differences in the endogenous IFN-like activity, we
looked for genes involved either in the pathways regulat-
ing IFN-beta expression or in the pathways triggered by
IFN-beta. We searched the PubMed database for review
articles published within the last 5 years addressing the
respective IFN-beta-related pathways. Eleven reviews
were selected [34-44], and we extracted the genes that
were redundantly mentioned in these publications to-
gether with their mutual interactions (Additional file 1).
A network of the genes visualizing the different types of
interactions (for example, binding, activation and inhib-
ition) was constructed using the Cytoscape software
version 2.8.1 (Cytoscape Consortium, San Diego, CA,
USA, http://www.cytoscape.org).
Experimental setup and microarray data
This study comprises 61 patients suffering from RR-MS
diagnosed according to the McDonald criteria [45]. The
patients were prescribed sc IFN-beta-1a (n=12), sc IFN-
beta-1b (n=25) or im IFN-beta-1a (n=24) treatment.
Blood samples were drawn immediately before the start of
therapy (baseline) and after 1 month prior to the next drug
application. Peripheral blood mononuclear cells (PBMC)
were separated from the blood samples by Ficoll gradient
and total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany). The RNA was processed, la-
beled and hybridized to Affymetrix HG-U133 A and B or
Plus 2.0 oligonucleotide microarrays according to the man-
ufacturer’s protocols. To calculate the gene expression
levels, we used custom chip definition files (CDFs) and ap-
plied the MAS5.0 algorithm. The custom CDFs (version
2.1.0, http://www.xlab.unimo.it/GA_CDF/) [46] define pro-
besets composed of probes matching only a single gene
based on the GeneAnnot (version 1.9) and GeneCards (ver-
sion 2.41) databases [47]. In this way, an accurate
assignment of probesets and genes could be achieved. This
gave us an expression data set of about 17,000 genes, cor-
rected for variation between the microarrays by loess
normalization. The full data are available in the GEO data-
base [GEO:GSE19285, GEO:GSE24427, GEO:GSE33464].
Further details on the experiments and the data preproces-
sing can be found elsewhere [48,49]. The studies were
approved by the University of Rostock’s ethics committee
and carried out according to the Declaration of Helsinki.
Written informed consent was obtained from all patients
before the blood sampling.
Statistical analysis of the gene expression data
Based on the baseline MX1 transcript levels as a meas-
ure of endogenous type I IFN-like activity, the patients
were divided into two groups. The detected MX1 signal
intensities varied from 875 to 11,588 (Additional file 2).
We set a cut-off at 3,000, which was two standard errors
above the mean. Patients with MX1 levels below the cut-
off were allocated to the MX1low cohort and those with
MX1 levels above the cut-off were allocated to the
MX1high cohort. The mean expression levels of the genes
involved in the IFN-beta-related pathways were then
compared between the MX1high group and the MX1low
group at baseline as well as after 1 month using the
Wilcoxon rank-sum test. We further compared the ex-
pression levels at both time-points within each group
using the Wilcoxon signed-rank test. Expression differ-
ences with P-values below 0.01 were considered statisti-
cally significant. For the gene expression comparisons,
only data from patients who received IFN-beta sc were
considered since, due to the different drug application
schedules for IFN-beta sc (3 to 4 injections per week)
and IFN-beta im (1 injection per week), the interval be-
tween two subsequent drug injections differs. Since the
blood sampling was always performed before the next
injection, this has a considerable influence on the mea-
sured mRNA levels [22,23]. Statistical analyses have been
computed with PASW Statistics version 18.0.0 (SPSS
Inc., Chicago, IL, USA) and the data were imported into
Cytoscape to visualize differences and changes in gene
expression.
Validation of the microarray data by real-time PCR
Quantitative real-time reverse transcription PCR was per-
formed to confirm the gene expression levels quantified
by the microarrays. The microarray experiments were
conducted between 2003 and 2007, and the real-time PCR
experiments were performed in 2012. Meanwhile, the total
RNA samples were stored at −25 °C. RNA quantity and
quality was determined using a NanoDrop 1000 Spectro-
photometer (Thermo Scientific, Wilmington, DE, USA)
and a 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA), respectively. For 44 of the 61 patients,
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sufficient amounts of PBMC RNA were available for both
the baseline sample and the sample obtained 1 month
after the start of treatment. A set of genes was re-
measured by real-time PCR in the samples of these
patients. From each sample, 0.2 μg total RNA was reverse
transcribed using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Carlsbad, CA, USA).
The obtained cDNA was then measured in 384-well
TaqMan Arrays with pre-designed TaqMan assay reagents
according to the manufacturer’s instructions with a
7900HT Sequence Detection System (Applied Biosys-
tems). The two samples from each patient were always
processed in one batch. Fluorescence was measured dur-
ing each PCR cycle, and thresholds at which the signal is
detected above background (Ct values) were computed
automatically using the SDS 2.3 and RQ Manager 1.2 soft-
ware (Applied Biosystems). For four patients, the real-time
PCR measurement was replicated. For those, we calcu-
lated the mean of the Ct values. The Ct values were then
utilized for the analysis of differential expression applying
Wilcoxon tests as described for the microarray data.
Spearman’s rank correlation coefficients and P-values were
computed to assess whether the real-time PCR data cor-
relate with the microarray data.
Stability of MX1 mRNA expression
An elevated type I IFN-like activity may either be char-
acteristic for some patients or may be only a temporary
phenomenon at the time of blood sampling (for ex-
ample, due to an undiagnosed viral infection). We there-
fore evaluated whether the natural MX1 expression is
stable over time using the Affymetrix microarray data by
Karlovich et al. [GEO:GSE16028] [50]. The data provide
whole blood gene expression levels of 22 healthy indivi-
duals measured at five different time-points spanning a
period of 6 months. We pre-processed the data in the
same manner as we pre-processed our own data (see
section “experimental setup and microarray data”). Cor-
relation of MX1 levels at study onset and after 6 months
was assessed by Spearman’s rho. We performed an ana-
lysis of variance (ANOVA) to explore the impact of age,
gender, time-point and the individual subjects on the
measured MX1 transcript signals. The linear ANOVA
model was fitted using the R package “car” with type II
sums of squares and F-test statistic.
Analysis of transcription factor binding sites
We examined the regulatory regions of all genes
involved in the IFN-beta-related signaling pathways for
putative DNA-binding sites for the transcription factor
complex ISGF3 (IFN-stimulated gene factor 3, Transfac
database sequence motif identifier V$ISRE_01). Predic-
tions of evolutionarily conserved transcription factor
binding sites (TFBS) provided by the tfbsConsSites track
(hg18) of the UCSC database were used for this purpose.
For each gene, the regulatory region was assumed to be
1,000 base pairs up- and downstream of the respective
transcription start site, which was taken from the Gene-
Cards database (version 2.41).
Clinical data evaluation
All patients were monitored for the occurrence of
relapses, and EDSS assessments were performed after
regular intervals of 3 months. The course of disease was
followed for 5 years, even if the patients terminated the
treatment during follow-up.
To detect possible pre-treatment differences in the pa-
tient population between the MX1high and the MX1low
groups, we compared age and EDSS at baseline, elapsed
time between diagnosis of definite MS and study onset,
as well as the number of relapses 1 year prior to the
study, applying the two-sample two-tailed t-test assum-
ing equal variances with significance level alpha = 0.05.
The sex ratio and the number of patients per adminis-
tered IFN-beta formulation were compared between the
cohorts with Fisher’s exact test at the alpha = 0.05 level
of significance. Furthermore, these patient parameters
were checked for correlation with the baseline expres-
sion levels of the pathway genes by calculating the Pear-
son correlation coefficient. Because of multiple testing,
only correlation P-values below 0.001 were considered
statistically significant.
We investigated the clinical relevance of endogenous
IFN-like activity on the long-term course of disease by
evaluating the progression of EDSS and the number of
relapses during a 5-year follow-up period after the start
of IFN-beta therapy. Mean EDSS scores and the cumula-
tive number of relapses have been compared between
the two patient groups using the t-test with Welch cor-
rection. Additionally, we compared the relapse-free sur-
vival during the follow-up by constructing right-
censored Kaplan-Meier curves with PASW Statistics.
The relapse-free survival curves for the MX1high patient
group and the MX1low patient group have been tested
for significant deviation by computing the log-rank test
and the Cox proportional hazard ratio.
Results
Interferon pathways
We identified 46 genes that have redundantly been
described in the literature to play a role in the pathways
inducing IFN-beta transcription and the pathway that is
activated by IFN-beta [34-44]. We complemented the list
of genes with 10 genes that have repeatedly been
reported as ISGs, including MX1 (Additional file 1). The
genes, and their interactions within the IFN-beta induc-
tion pathways and the IFN-beta effector pathway, will be
summarized briefly below.
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The expression of IFN-beta is physiologically induced
after recognition of viral, bacterial or degraded endogen-
ous nucleic acids by cellular receptors. This is mediated
by the activation of two main pathways. The endosomal
Toll-like receptors (TLRs) TLR7, -8 and -9 activate a
MyD88-dependent pathway with the signal transducers
IRAK4, IRAK1 and TRAF6. The latter leads via MAP3K7
(TAK1) to the phosphorylation of the kinases IKK,
MAPK8 (JNK) and MAPK14 (p38), resulting in the acti-
vation of the transcription factors NFkappaB, JUN and
ATF2, respectively. The other main pathway is initiated
by the endosomal TLR3, as well as by the cytoplasmic
receptors IFIH1 (MDA5), DDX58 (RIG-I) and ZBP1.
They induce the phosphorylation of the IFN regulatory
factors (IRF) IRF3 and IRF7 via TRAF3 and TBK1/IKK-
epsilon. These IRFs then homodimerize or heterodimer-
ize and translocate to the nucleus. The cell membrane-
bound TLR4 can initiate both the MyD88 pathway and
the TRAF3 pathway. The activated TFs bind to the pro-
moter region of IFN-beta (IFNB1) and initiate its tran-
scription [51]. Several cross-bridges between the MyD88
and the TRAF3 pathway exist [34-38,40,41,43,44].
Endogenously produced IFN-beta and exogenously
injected IFN-beta bind to the IFN-alpha/beta receptor.
This receptor comprises the subunits IFNAR1 and
IFNAR2 with the associated kinases TYK2 and JAK1.
Once activated, the IFNAR complex phosphorylates
STAT1 and STAT2, which heterotrimerize with IRF9 to
form the ISGF3 complex (JAK/STAT pathway). ISGF3
translocates to the nucleus and binds the interferon-
stimulated response element (ISRE), a DNA motif that
can be found in the regulatory region of many ISGs.
Activated STATs also form homodimers and heterodi-
mers acting as TFs independent of IRF9 [35-40,42,43].
The activation of STATs in response to IFN-beta was
shown to differ among leukocyte subsets, with STAT1
being mainly activated in monocytes and CD8+ T cells
[52].
There are several positive and negative feedback loops
in the type I IFN-related pathways. Many receptors, sig-
nal transducers and TFs within the IFN-beta induction
pathway are themselves induced by IFNs, thereby ampli-
fying IFN responses, for example IRF7, DDX58 and
IFIH1 [37,39]. As a negative feedback, the JAK/STAT
pathway stimulates the transcription of several suppres-
sor of cytokine signaling (SOCS) genes, which act as
inhibitors on TLRs and JAKs, and target the IFNAR
complex for proteasomal degradation [35].
Patient characteristics
The 61 RR-MS patients (42 females, 19 males) in our
study were between 18 and 63 years of age at the start of
treatment with IFN-beta. The time elapsed between
diagnosis of MS and therapy initiation was less than
9 months for 53 patients and between 25 and
134 months for the remaining 8 patients. At the time of
blood sampling, there was no evidence of an ongoing in-
fection based on clinical signs and laboratory testing.
Over the complete 5-year observation period, 55 of the
61 patients have been followed at our clinic and 41
patients continuously received the prescribed IFN-beta
therapy. Eleven of the 61 patients had relatively elevated
baseline MX1 expression levels. They were allocated to
the MX1high cohort, while the remaining 50 patients
were allocated to the MX1low cohort. There was no sig-
nificant difference between the two patient groups in
terms of age, sex ratio and baseline EDSS. The time be-
tween diagnosis and study onset, as well as the number
of relapses during the year prior to the study, were com-
parable (Table 1). No significant correlation between any
of these patient characteristics and the pre-treatment ex-
pression levels of the 56 pathway genes could be
observed.
Expression levels and dynamics dependent on MX1 status
For comparison of the PBMC gene expression between
the two patient groups and between the two time-
points, only patients who received IFN-beta sc were con-
sidered (see Methods). Of these individuals, 7 patients
were in the MX1high group and 30 patients were in the
MX1low group. After 1 month of therapy, the MX1 ex-
pression levels of the MX1high cohort remained relatively
unchanged whereas MX1low patients showed a signifi-
cant induction up to the levels of the MX1high group
(Figure 1). Similar expression patterns were observed for
other ISGs.
When comparing the mean baseline expression of the
56 pathway genes between both cohorts, 11 genes were
expressed in the MX1high group at a significantly higher
level. Elevated transcript levels were found for cytoplas-
mic receptors (for example, IFIH1), TFs (for example,
IRF7, IRF9 and STAT1) and, as expected, most ISGs
(Figure 2 and Additional file 3). Other receptors, such as
TLR7 and TLR8, as well as the transcription factor
STAT2, also showed elevated expression in MX1high
patients, but with P-values> 0.01. We found no signifi-
cant difference in expression at the mRNA level for nat-
ural IFN-beta (IFNB1) and its receptors IFNAR1 and
IFNAR2.
During the first month of IFN-beta sc therapy, the
MX1high group showed no significant change in the expres-
sion of the IFN-beta-related pathway genes (Additional file
4). In contrast, 25 of the 56 genes were found to be signifi-
cantly modulated in MX1low patients, with 23 genes being
upregulated and two genes (TLR9 and IRAK4) being
downregulated in response to therapy (Figure 3). The upre-
gulated genes comprised all the 11 genes that were signifi-
cantly elevated in the MX1high patient group at baseline.
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After 1 month of therapy, there was no difference in ex-
pression of the genes between the two patient groups
(Additional file 5).
The differences in gene expression over time and be-
tween the cohorts are summarized in Figure 4 and in
Additional file 3. The pathway visualizations are avail-
able from the authors as Cytoscape session files upon
request.
Real-time PCR analysis of differential gene expression
Of the 56 pathway genes, 14 were re-measured by real-
time PCR. Overall, the PCR analyses confirmed the
microarray results. Despite the long storage of the sam-
ples, the mRNA levels obtained by the two techniques
correlated significantly for all genes except TLR9
(Additional file 2). Of the 11 MX1high patients, nine were
contained in the PCR data. As in the microarray data,
they also showed a higher pre-treatment expression of
MX1 (Ct values< 26.7) than all MX1low patients in the
PCR data. In the subgroup of patients treated with IFN-
beta sc, there were five MX1high patients and 21 MX1low
patients. Although sample sizes were smaller, the expres-
sion differences observed in the Affymetrix microarray
data were also seen in the real-time PCR data: at base-
line, MX1, MYD88, RSAD2, STAT1 and STAT2 were
expressed at higher levels in MX1high patients, and they
were significantly upregulated during therapy only in the
MX1low cohort (Additional file 3).
ISGF3 is a central regulator of type I IFN signaling
Predicted TFBS for ISGF3 were found in the promoter
regions of 10 out of the 56 pathway genes (Additional
file 3). There was a marked overlap when comparing the
genes putatively regulated by the ISGF3 complex with
those genes overexpressed in MX1high patients at base-
line. The receptors IFIH1, DDX58 and ZBP1, two ISGs
(CXCL10, ISG20), IFNB1, the pathway inhibitors SOCS1
and SOCS3, as well as the TFs IRF7 and STAT2 con-
tained predicted DNA-binding sites for ISGF3 in their
promoter region. In this way, ISGF3 forms multiple
positive and negative regulatory feedback loops. We con-
clude from this analysis that a higher expression and ac-
tivity of the ISGF3 complex is most likely responsible for
the higher endogenous type I IFN-like activity seen in a
subset of patients.
Stability of MX1 mRNA expression
In the time-course expression data by Karlovich et al.
[50], we observed that approximately one-fifth of the
healthy subjects showed relatively elevated MX1 tran-
script levels in the blood, which is very similar to the
proportion we ascertained for the MS patients in our
study. Differential endogenous type I IFN-like activities
therefore seem to be not exclusive for MS patients, and
may rather demonstrate individual variation of innate
immunity. Moreover, high MX1 expression at study
onset correlated strongly with the levels measured after
6 months (P= 0.00003). This revealed that the natural
course of MX1, and thus the IFN-beta-like activity, is
stable over time. ANOVA confirmed this result; the vari-
ance in the data could be explained best by intersubject
Figure 1 MX1 expression levels immediately before and
1 month after the start of therapy with subcutaneous IFN-beta.
The measured signal intensities are presented in log scale due to
the skewed data distribution. Patients with elevated MX1 transcript
levels at baseline (MX1high, n = 7, black dots) showed only a weak
gene induction after 1 month of treatment (P-value = 0.156). In
contrast, individuals in the MX1low group (n = 30, red dots) had a
significant increase in expression up to the levels of the MX1high
group (P-value = 1.9 × 10-9). The figure was drawn using the function
“ehplot” of the R package “plotrix”.
Table 1 Clinical and demographic parameters of the two patient cohorts
Demographic and clinical characteristics MX1high (n =11) MX1low (n = 50) P - value
Age at study onset (years) 34.8 ± 8.7 38.3 ± 10.4 0.312
Time from diagnosis to therapy (months) 2.4 ± 2.4 11.6 ± 26.6 0.258
EDSS at baseline 2.0 ± 1.5 1.7 ± 1.1 0.510
Number of relapses during the year prior to study onset 1.2 ± 0.4 0.9 ± 0.6 0.172
Gender (women/men) 8/3 34/16 1.000
Type of IFN-beta administered (1a im/1a sc/1b sc) 4/3/4 20/9/21 0.826
Mean± standard deviation are given for age, disease duration and expanded disability status scale (EDSS) at study onset as well as for the number of relapses in
the year prior to treatment. These parameters were tested for differences between patients with low and high endogenous IFN-like activity (patient groups
MX1low and MX1high) applying the t-test. For the sex ratio and the administered IFN-beta products, the absolute patient numbers are given and P-values as
calculated by Fisher’s exact test. im, intramuscular; sc, subcutaneous.
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differences (P= 3.6 × 10-12), while the effects of age and
gender were not significant. The MX1 expression data of
the 22 healthy individuals are shown in Additional file 6.
MX1 status and clinical outcome
To evaluate whether the endogenous IFN-beta-like
activity is associated with individual disease progres-
sion and IFN-beta therapy outcome, we compared the
MX1high group and the MX1low group in terms of
EDSS and relapses as clinical measures of the long-
term course of disease. The EDSS-defined changes of
disability differed considerably between the individual
patients. However, when comparing the mean EDSS
of the two patient groups, the course of progression was
very similar (Figure 5). After 5 years, the EDSS of the
MX1high cohort and the MX1low cohort had risen, on aver-
age, by 0.85 and 0.92 points, respectively. The mean 5-year
relapse rate also did not differ significantly between the
MX1high group (1.6) and the MX1low group (1.7) (Figure 5).
Accordingly, the Kaplan-Meier curves for relapse-free
survival of both groups were very similar in their decline,
especially during the first 2 years (Figure 6). For the
complete 5-year follow-up period the calculated log-rank
statistic (P=0.424) and the hazard ratio (0.68, confidence
interval: 0.27 to 1.76) showed no significant difference in
the proportion of relapse-free patients between the cohorts.
Figure 2 Pre-treatment expression of TLR, RIG-I and IFN-beta pathway genes compared between the two patient groups. The pathways
that induce type I IFN expression via TRAF3 and MyD88 are shown on the left and the pathway that is triggered by IFN-beta (JAK/STAT pathway)
is shown on the right. Each gene is colored by the magnitude of mean expression difference between the MX1high group (n = 7) and the MX1low
group (n = 30). Black node labels indicate significant differences (P-value< 0.01). Aside from MX1 as an established biomarker of IFN activity, other
ISGs also showed higher levels of expression in the MX1high patient cohort before initiation of subcutaneous IFN-beta therapy. The elevated
endogenous IFN-like activity of these patients is likely the result of elevated amounts of the transcription factors STAT1, STAT2 and IRF9, which
form the ISGF3 complex. DNA-binding sites for this complex can be found in the promoters of RIG-I-like helicases (IFIH1, DDX58), suppressor of
cytokine signaling (SOCS) genes and the transcription factor IRF7, which were also expressed at higher levels in MX1high patients (see Additional
file 3). Other genes such as IRF3, the NFkappaB members, IFNB1 and the IFN-alpha/beta receptors were not differentially expressed.
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However, when comparing the relapse rate between
MX1high patients and MX1low patients separately for the
three different drug formulations, we could observe
significant differences (Additional files 7 and 8). In the
subgroup of patients treated with IFN-beta-1a im, all the
MX1high patients (n = 4) were free of relapses over 5 years
whilst the MX1low patients (n = 17) experienced 1.6
relapses on average. In contrast, within the patient group
receiving IFN-beta-1b sc, the MX1high cohort (n = 3) had
a much higher average number of relapses than the
MX1low cohort (n = 20) (2.7 versus 1.3). MX1high patients
and MX1low patients had similar changes on the EDSS
for each of the drug preparations. However, patients re-
ceiving IFN-beta im were diagnosed and treated at an
earlier stage of the disease (mean baseline EDSS: 1.0)
than those receiving IFN-beta sc (mean baseline EDSS:
2.3), and they were also more stable during the follow-
up period.
Discussion
Our results revealed that approximately one-fifth of MS
patients show an elevated endogenous type I IFN-like
activity prior to IFN-beta treatment and that this
phenomenon can be explained by a higher expression
and activity of the ISGF3 complex. This complex com-
prises the TFs STAT1, STAT2 and IRF9, and is not just a
key regulator of ISGs, but is also important to induce di-
verse genes involved in IFN regulation and signaling
[37,53]. Therefore, patients with high levels of the IFN
activity biomarker MX1 (MX1high cohort) also showed
high levels of other ISGs and several pathway genes,
which in turn can control type I IFN transcription, form-
ing positive feedback loops [39]. The link between ISGF3
and IFN-like expression signature is supported by the
results of the TFBS analysis, which revealed that the list
of ISGF3 target genes to a certain extent resembles the
list of genes elevated in MX1high patients. Our study is
Figure 3 IFN-beta-related pathways and gene expression changes in MX1low patients during the first month of IFN-beta therapy. The
log-2 ratios of the mean gene expression levels before and after 1 month of subcutaneous IFN-beta therapy are shown by the color of the gene
nodes. Genes with significant expression changes are labeled in black (P< 0.01). Receptors, transcription factors and ISGs that were elevated in
the MX1high group (n = 7) at baseline (Figure 2) were strongly upregulated under therapy in MX1low patients (n = 30), whereas TLR9 and IRAK4
were significantly downregulated in this patient group.
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limited by the fact that we measured the gene expression
in PBMCs at the mRNA level, which does not necessar-
ily correlate with the amounts of active proteins due to
post-transcriptional gene regulation, for example by
microRNAs [54,55]. However, earlier studies at the pro-
tein level have already shown that the phosphorylation
status of the ISGF3 component STAT1 correlates with
the ISG expression in MS patients [31].
We observed increased pre-treatment levels of the
single-stranded RNA receptors TLR7 and TLR8 in
MX1high patients compared with MX1low patients. This
may also be mutually linked to an overactive JAK/STAT
pathway in the MX1high group of patients. The expres-
sion differences for these two TLR receptors did not
reach the significance threshold (P-values< 0.01). How-
ever, this may be due to the fact that a different Affyme-
trix chip type (U133 Plus 2.0) was used for the samples
of patients treated with IFN-beta-1a sc than for the
others (U133 A and B). For some genes, including these
two TLRs, differences in the custom probesets between
both chip types led to increased variation in the data
and thus somewhat higher P-values (Additional files 2
and 3).
Similar to our patients, we also found a relatively
high type I IFN-like activity in a subset of healthy
individuals, and MX1 levels in the respective indivi-
duals remained elevated over the whole study period
of 6 months. Therefore, independent of MS disease,
some people seem to have a constitutive, robust sig-
nature of immune activation, while others do not. It
has been described that the immune defense program
is, in general, slightly more active in MS [26,56].
However, we could not evaluate this aspect, since we
used external data on the whole blood of healthy sub-
jects where it is difficult to compare the absolute
mRNA signals with our PBMC data on MS patients.
Still, the data on the healthy subjects provided strong
evidence that the observed increased IFN-beta-like ac-
tivities are not just the result of short-term hidden
viral infections. This is further supported by our find-
ing that the IFN-beta gene itself (IFNB1) was not
expressed at higher levels in the MX1high group as
would be expected during an activated antiviral re-
sponse (hence we used the term “IFN-like activity”).
However, IFNB1 transcript levels were virtually un-
detectable in our Affymetrix microarray data (Add-
itional file 2), and we have not measured them with
real-time PCR. Others have used more sensitive
methods and could detect an elevated endogenous
IFN-beta expression in PBMCs at baseline in IFN-
beta therapy non-responders [29], which they believed
to be causal for an elevated type I IFN signature [28].
Figure 4 Summary of the gene regulatory effects of IFN-beta
therapy and the differences in expression between the two
patient cohorts. Before the start of therapy, 11 genes were
expressed at significantly higher levels in the group of patients with
elevated IFN-like activity (MX1high, n = 7). The pathway expression
profile of those patients was not significantly influenced by
subcutaneous IFN-beta therapy. In comparison, 25 genes were
up- or downregulated in response to therapy in the MX1low group
(n = 30), including all 11 genes that were elevated in the MX1high
group at baseline. After 1 month of therapy, no significant
differences in gene expression could be observed between the
cohorts.
Figure 5 Long-term progression of disability and cumulative
number of relapses. Mean time-courses are shown in black for the
MX1high group and in red for the MX1low group. The change of
disability according to the expanded disability status scale (EDSS) as
well as the relapse rate during the 5-year follow-up period were
similar for both cohorts (Welch’s t-test P-values> 0.2). MX1high
patients presented on average a slightly worse EDSS at baseline, and
this nonsignificant difference persisted during the treatment. Error
bars represent standard errors.
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We could not confirm these conclusions with the
data from our study.
During IFN-beta sc therapy, patients with relatively
high ISG expression at baseline showed no significant
modulation in the expression of the genes involved in
IFN-beta-related pathways. In contrast, patients in the
MX1low group showed a strong gene induction after
1 month of treatment (Figure 4). The congruency be-
tween the set of genes primarily elevated in MX1high
patients and the genes induced by therapeutic IFN-beta
in MX1low patients was striking. Possibly, higher levels
of MX1 and its co-expressed genes might be observed
during therapy in both patient groups, if the blood
expression is measured in the first 12 h after an IFN-
beta injection [22,23]. Moreover, since we only measured
the changes in mRNA expression, additional experi-
ments on the protein level are needed to further investi-
gate specific issues, for example the correlation between
the amounts of STAT transcripts and the amounts of
phosphorylated STAT proteins. Similarly, while we
observed no significant blood expression differences for
IFN-alpha/beta receptors, we can only speculate about
the amounts and cell type-specific localization of the
corresponding proteins. Comabella et al. [28,29] used
flow cytometry to measure the expression of IFNAR1 on
monocytes. In patients with ongoing disease activity des-
pite IFN-beta treatment, they found a higher baseline
expression of this receptor [28,29]. Dupont et al. [57]
showed, using in vitro experiments with Jurkat cells, that
the surface expression of IFNAR1 decreases after IFN-
beta application and that the cells were subsequently
unresponsive to further IFN-beta treatment for some
hours. We may miss such findings in the PBMC popula-
tion. Additionally, receptor polymorphisms, or alterna-
tively spliced transcripts of these receptors, could play a
role. Different splice variants of the IFNAR2 receptor
show different biologic responses to endogenous and ex-
ogenous IFN-beta and there is evidence that IFN-beta
immunogenicity may be, in part, related to IFNAR2 iso-
form expression [58]. However, since NAbs were not
routinely measured for our patients, we were not able to
investigate this possible association of IFNAR expression
and NAbs.
A further interesting observation was that the levels of
TLR3 and -7 were significantly upregulated, while TLR9
was significantly downregulated, in MX1low patients dur-
ing therapy. Pre-treatment levels of TLR3 were some-
what lower for MX1high patients (P= 0.059), but the
expression also strongly increased within 1 month of
IFN-beta administration in this patient group (P= 0.016).
TLR7 is engaged in the maturation of dendritic cells,
which play a role in bridging innate and adaptive im-
munity [59]. Upregulation of TLR7 on dendritic cells by
IFN-beta has been shown to inhibit the differentiation of
Th17 cells [60], which have been recognized as proin-
flammatory lymphocytes involved in MS pathogenesis
[61]. TLR-mediated signaling and IFN signaling is
counter-regulated by SOCS1, the mRNA levels of which
were upregulated in the MX1low patient group during
therapy (P= 0.017). A genetic risk factor for MS has
been identified in the SOCS1 promoter region recently
[62].
We addressed the clinical importance of endogenous
IFN-like activity and its prognostic power to predict disease
progression and clinical response to IFN-beta therapy, an
issue that has been debated with contradictory results
[27-33]. Some studies suggest that baseline overexpression
of ISGs may indicate pre-activated pathways in a way that
IFN injections are less effective, which may explain subopti-
mal therapeutic responses [28,30]. However, a correlation
between an elevated endogenous type I IFN signature and a
worse course of disease could not be confirmed in our
study, even though the MX1high patient group showed a
much weaker biologic response within the first treatment
month, at least regarding the mRNA levels of the 56 exam-
ined pathway genes. Over the 5-year follow-up period, nei-
ther the average number of relapses nor the increase in
EDSS were significantly different between patients with low
and high baseline MX1 levels. On the contrary, in a study
Figure 6 Kaplan-Meier survival curves for patients with low and
high endogenous IFN-like activity. The Kaplan-Meier curves show
the proportion of relapse-free patients in the MX1high group (black
curve) and in the MX1low group (red curve). Vertical dashes indicate
right-censored patients that dropped out of clinical surveillance
(n = 3). In particular, during the first 18 months after therapy
initiation, the proportions of relapse-free patients declined in a
similar manner for both cohorts. Overall, the difference between
both patient groups was not significant according to the log-rank
test (P= 0.424) and the hazard ratio (0.684, confidence interval: 0.266
to 1.761).
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by van der Voort et al. [32], high MX1 mRNA expression
was predictive of a longer time to a first new relapse. How-
ever, less than half of their patients that were initially
therapy-naive started an immunomodulatory treatment
during follow-up, and the baselineMX1 levels did not differ
significantly between responder status groups for the subset
of treated patients. The beneficial effect of an increased
IFN-like activity thus may be observed primarily in un-
treated patients. This is supported by the results of Hesse et
al. [33], who found an indirect negative correlation between
the number of active lesions and the blood expression of
MX1 in untreated patients. We hypothesize that a higher
endogenous IFN-like activity does not imply IFN-beta ther-
apy non-response, but might be positive in untreated
patients. Nevertheless, the question remains whether
MX1high patients could benefit more from other treatments
than from IFN-beta.
Our analysis revealed some differences in the relapse
rates of the MX1high group and the MX1low group when
analyzing the data for each IFN-beta drug preparation sep-
arately. However, this result must be interpreted with cau-
tion for two reasons: firstly, for each of the three therapy
regimes, the number of patients per MX1 group is relatively
small; and secondly, we did not systematically test for NAbs
after long-term treatment, but their appearance might have
led to reduced therapeutic benefits in some of the patients.
In our data, MX1high patients treated with once weekly
30 μg IFN-beta-1a im experienced no relapse during the
5-year follow-up period, while MX1high patients receiving
high-frequent high-dose IFN-beta-1b sc experienced, on
average, 2.7 relapses. It is tempting to speculate about the
reasons for this discrepancy. One possible explanation
might be that only intermediate levels of IFN-beta are bene-
ficial. Patients with low inherent type I IFN-like activity
might need frequent IFN-beta therapy, whereas in MX1high
patients such a more intense IFN administration may not
yield the desired effects, and possibly raises the chance of
NAb development. An alternative explanation might be
found in the disease duration. Patients treated with IFN-
beta-1a im were, according to the EDSS at study onset, in
an earlier stage of MS, and it is thus conceivable that a
higher endogenous IFN signature combined with IFN-beta
treatment might be preferentially favorable early in disease.
Therapy-specific studies with larger cohorts are needed to
test whether MX1 has the potential to support the choice
of IFN-beta drug preparation for the individual patient.
Such further investigations must carefully consider the
issues of dosage and frequency of IFN-beta administration,
and should take the issue of NAbs into account.
Conclusions
In conclusion, an elevated type I IFN-like activity was
observed in the blood of a subset of MS patients as well
as a subset of healthy individuals. We showed for the
healthy subjects that this gene expression signature is
robust over time and is therefore probably not the result
of a transient latent infection. For the MS patients we
demonstrated that the expression of genes involved in
IFN-related pathways is strongly induced by IFN-beta
therapy in those patients with low endogenous IFN-like
activity, but is only weakly induced in patients with high
endogenous IFN-like activity. The baseline gene expres-
sion pattern characteristic for the latter group resembles
the pattern induced by therapeutic IFN-beta. While the
natural IFN-beta and its receptors were expressed at
similar mRNA levels in both groups, genes of the ISGF3
transcription factor complex were expressed significantly
more in patients with an elevated endogenous IFN-beta-
like signature. Our TFBS analysis led us to the hypoth-
esis that the activity of the ISGF3 complex is crucial for
the individually different activation status of the IFN
pathways. Our study, which was limited by a relatively
small sample size, did not confirm that the IFN signature
prior to treatment with IFN-beta is predictive of the in-
dividual long-term course of MS, but different outcomes
were observed for different drug formulations. This
deserves further investigation with more sensitive and
cell type-specific analyses on the RNA and protein level.
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genes involved in IFN-related pathways.
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data of the 56 pathway genes for all 61 patients before therapy
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were obtained for 44 of the patients.
Additional file 3: Genes involved in the pathways regulating IFN-
beta expression and in the pathway that is activated by IFN-beta.
Mean microarray signal intensities, calculated Wilcoxon test P-values as
well as ISGF3 DNA-binding site information are provided for all genes.
Moreover, for 14 of the genes, the results of the real-time PCR analysis
are also shown.
Additional file 4: IFN-beta-related signaling pathways displaying
the pharmacological effects on gene expression for the MX1high
patient group after 1 month of treatment with IFN-beta sc.
Additional file 5: Expression of TLR, RIG-I and IFN-beta pathway
genes compared between both cohorts at 1 month after start of
IFN-beta sc therapy.
Additional file 6: The natural course of MX1 mRNA expression is
shown for 22 healthy individuals over a period of 6 months.
Additional file 7: Comparison between both cohorts in terms of
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Additional file 8: The proportion of relapse-free patients during
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